Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.37 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.35 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.35 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.35 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.95 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL551145 | 0.98 | MAPK1 (1.00) | MAPK1MEN1KMT2ACHRNB4CHRNA3 | |
| SCHEMBL13908059 | 0.98 | MAPK1 (1.00) | MAPK1MEN1KMT2ACHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL989897 | 0.90 | MAPK1 (0.77) | MAPK1MEN1KMT2A | |
| SCHEMBL113382 | 0.87 | MAPK1 (0.81) | MAPK1MEN1KMT2A | |
| SCHEMBL6018054 | 0.87 | MAPK1 (0.81) | MAPK1MEN1KMT2A | |
| SCHEMBL20906278 | 0.87 | MAPK1 (0.81) | MAPK1MEN1KMT2A | |
| SCHEMBL113383 | 0.87 | MAPK1 (0.81) | MAPK1MEN1KMT2A | |
| SCHEMBL18322806 | 0.80 | MAPK1 (0.70) | MAPK1MEN1KMT2A | |
| SCHEMBL23475180 | 0.77 | MAPK1 (0.65) | MAPK1MEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL3412272 | 0.77 | MAPK1 (0.65) | MAPK1MEN1KMT2ACHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004701-B2 | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (US) | 2018-06-26 | — | — | US | disclosed |
| US-9983218-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9625475-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | UNIVERSITY OF ROCHESTER (US) | 2017-03-09 | — | — | US | disclosed |
| US-9393221-B2 | Methods and compounds for reducing intracellular lipid storage | THE GENERAL HOSPITAL CORPORATION (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-9063126-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-8575186-B2 | Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| EP-0711299-B1 | AZABICYCLOALKYL DERIVATIVES OF IMIDAZO(1,5-a)INDOL-3-ONE AS 5HT 3 ANTAGONISTS | PHARMACIA & UPJOHN SPA (IT) | 2000-01-05 | — | — | EP | disclosed |
| US-5637596-A | REACTING AMINOMETHYLINDOLE DERIVATIVE WITH A CARBONYL CONTAINING CYCLIZING AGENT; 5-HT3 RECEPTOR ATAGONIST; USEFUL FOR TREATING ANXIETY, PSYCHOSIS, GUT MOTILITY DISORDER, EMESIS, MIGRAINE AND DRUG ADDICTION | PHARMACIA S.P.A. (IT) | 1997-06-10 | — | — | US | disclosed |
| EP-0711299-A1 | AZABICYCLOALKYL DERIVATIVES OF IMIDAZO(1,5-a)INDOL-3-ONE AS 5HT 3 ANTAGONISTS | PHARMACIA & UPJOHN S.p.A. (IT) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995032209-A1 | AZABICYCLOALKYL DERIVATIVES OF IMIDAZO(1,5-a)INDOL-3-ONE AS 5HT3 ANTAGONISTS | PHARMACIA S.P.A. (IT) | 1995-11-30 | — | — | WO | disclosed |
| US-5364854-A | Nervous system and gastrointestinal disorders; antiemetic, anxiolytic, and analgesic agents; cognition activators; drug abuse | FARMITALIA CARLO ERBA S.R.L. (IT) | 1994-11-15 | — | — | US | disclosed |
| EP-0606421-A1 | DERIVATIVES OF IMIDAZO 5,1-C] 1, 4]BENZOXAZIN-1-ONE AS 5 HT3 ANTAGONISTS | PHARMACIA & UPJOHN S.p.A. (IT) | 1994-07-20 | — | — | EP | disclosed |
| EP-0319429-B1 | 9-Acylamino-tetrahydroacridine derivatives and memory enhancing agent containing said derivative as active ingredient | MITSUBISHI CHEM IND (JP) | 1994-04-27 | — | — | EP | disclosed |
| WO-1993025555-A1 | DERIVATIVES OF IMIDAZO [5,1-C][1, 4]BENZOXAZIN-1-ONE AS 5 HT3 ANTAGONISTS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1993-12-23 | — | — | WO | disclosed |
| US-4985430-A | ALZHEIMER*S DISEASE | MITSUBISHI KASEI CORPORATION (JP) | 1991-01-15 | — | — | US | disclosed |
| EP-0319429-A2 | 9-Acylamino-tetrahydroacridine derivatives and memory enhancing agent containing said derivative as active ingredient | MITSUBISHI KASEI CORPORATION (JP) | 1989-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | CHRNB4 4829/4885CHRNA3 4818/4885CHRM2 4331/4885 |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | CHRNB4 701/4885CHRNA3 428/4885CHRM2 7/4885 |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | CHRNB4 4829/4885CHRNA3 4818/4885CHRM2 4331/4885 |
| US-10004701-B2 | Methods and compositions for treating infection | MMP8, IFNG, MPO | CHRNB4 4829/4885CHRNA3 4818/4885CHRM2 4331/4885 |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | CHRNB4 701/4885CHRNA3 428/4885CHRM2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.